249 related articles for article (PubMed ID: 14871939)
1. DNA repair functions that control sensitivity to topoisomerase-targeting drugs.
Malik M; Nitiss JL
Eukaryot Cell; 2004 Feb; 3(1):82-90. PubMed ID: 14871939
[TBL] [Abstract][Full Text] [Related]
2. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
3. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
[TBL] [Abstract][Full Text] [Related]
4. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
5. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.
Eng WK; Faucette L; Johnson RK; Sternglanz R
Mol Pharmacol; 1988 Dec; 34(6):755-60. PubMed ID: 2849043
[TBL] [Abstract][Full Text] [Related]
6. Characterization of RAD52 homologs in the fission yeast Schizosaccharomyces pombe.
van den Bosch M ; Vreeken K; Zonneveld JB; Brandsma JA; Lombaerts M; Murray JM; Lohman PH; Pastink A
Mutat Res; 2001 Jan; 461(4):311-23. PubMed ID: 11104907
[TBL] [Abstract][Full Text] [Related]
7. Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks.
Sabourin M; Nitiss JL; Nitiss KC; Tatebayashi K; Ikeda H; Osheroff N
Nucleic Acids Res; 2003 Aug; 31(15):4373-84. PubMed ID: 12888496
[TBL] [Abstract][Full Text] [Related]
8. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.
Nitiss JL; Liu YX; Hsiung Y
Cancer Res; 1993 Jan; 53(1):89-93. PubMed ID: 8380128
[TBL] [Abstract][Full Text] [Related]
9. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
10. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Christmann M; Tomicic MT; Gestrich C; Roos WP; Bohr VA; Kaina B
DNA Repair (Amst); 2008 Dec; 7(12):1999-2009. PubMed ID: 18805512
[TBL] [Abstract][Full Text] [Related]
11. Cell-based assays for identification of novel double-strand break-inducing agents.
Dunstan HM; Ludlow C; Goehle S; Cronk M; Szankasi P; Evans DR; Simon JA; Lamb JR
J Natl Cancer Inst; 2002 Jan; 94(2):88-94. PubMed ID: 11792746
[TBL] [Abstract][Full Text] [Related]
12. Distinct requirements for the Rad32(Mre11) nuclease and Ctp1(CtIP) in the removal of covalently bound topoisomerase I and II from DNA.
Hartsuiker E; Neale MJ; Carr AM
Mol Cell; 2009 Jan; 33(1):117-23. PubMed ID: 19150433
[TBL] [Abstract][Full Text] [Related]
13. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.
Maede Y; Shimizu H; Fukushima T; Kogame T; Nakamura T; Miki T; Takeda S; Pommier Y; Murai J
Mol Cancer Ther; 2014 Jan; 13(1):214-20. PubMed ID: 24130054
[TBL] [Abstract][Full Text] [Related]
14. Role of nucleotide excision repair proteins in response to DNA damage induced by topoisomerase II inhibitors.
Rocha JC; Busatto FF; Guecheva TN; Saffi J
Mutat Res Rev Mutat Res; 2016; 768():68-77. PubMed ID: 27234564
[TBL] [Abstract][Full Text] [Related]
15. Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons.
van Waardenburg RC; de Jong LA; van Delft F; van Eijndhoven MA; Bohlander M; Bjornsti MA; Brouwer J; Schellens JH
Mol Cancer Ther; 2004 Apr; 3(4):393-402. PubMed ID: 15078982
[TBL] [Abstract][Full Text] [Related]
16. The topoisomerase I poison camptothecin generates a Chk1-dependent DNA damage checkpoint signal in fission yeast.
Wan S; Capasso H; Walworth NC
Yeast; 1999 Jul; 15(10A):821-8. PubMed ID: 10407262
[TBL] [Abstract][Full Text] [Related]
17. Evidence for a role of vertebrate Rad52 in the repair of topoisomerase II-mediated DNA damage.
Adachi N; Iiizumi S; Koyama H
DNA Cell Biol; 2005 Jun; 24(6):388-93. PubMed ID: 15941391
[TBL] [Abstract][Full Text] [Related]
18. Mms22p protects Saccharomyces cerevisiae from DNA damage induced by topoisomerase II.
Baldwin EL; Berger AC; Corbett AH; Osheroff N
Nucleic Acids Res; 2005; 33(3):1021-30. PubMed ID: 15718301
[TBL] [Abstract][Full Text] [Related]
19. Differential expression and requirements for Schizosaccharomyces pombe RAD52 homologs in DNA repair and recombination.
van den Bosch M; Zonneveld JB; Vreeken K; de Vries FA; Lohman PH; Pastink A
Nucleic Acids Res; 2002 Mar; 30(6):1316-24. PubMed ID: 11884628
[TBL] [Abstract][Full Text] [Related]
20. The novel gene mus7(+) is involved in the repair of replication-associated DNA damage in fission yeast.
Yokoyama M; Inoue H; Ishii C; Murakami Y
DNA Repair (Amst); 2007 Jun; 6(6):770-80. PubMed ID: 17307401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
